Contact
searchSearch
HMP Global

Type 2 Inflammation Topic Center

Featured Article

Quiz
Utilization and Spending Changes With Preventive Drug Lists
12/12/2023
True or False: A case-control study found that exempting asthma medications from the deductible through preventive drug lists was associated with a modest absolute increase in adherence to controller medications and significantly reduced...
True or False: A case-control study found that exempting asthma medications from the deductible through preventive drug lists was associated with a modest absolute increase in adherence to controller medications and significantly reduced...
True or False: A case-control...
12/12/2023
First Report Managed Care
News
Utilization Increases and Spending Decreases With Preventive Drug Lists for Asthma Medications
11/29/2023
Lisa Kuhns, PhD, MD
Reducing cost-sharing for asthma medications through a preventive drug list (PDL) increases adherence to controller medications, according to a study published in JAMA Network Open.
Reducing cost-sharing for asthma medications through a preventive drug list (PDL) increases adherence to controller medications, according to a study published in JAMA Network Open.
Reducing cost-sharing for asthma...
11/29/2023
First Report Managed Care
News
Asthma Management Critical During Pregnancy
11/21/2023
Jolynn Tumolo
Potential roadblocks to adequate management of asthma in pregnant women include nonadherence to medication, lack of education, and smoking habits. The review mentions a retrospective study that found pregnant women with asthma tended to...
Potential roadblocks to adequate management of asthma in pregnant women include nonadherence to medication, lack of education, and smoking habits. The review mentions a retrospective study that found pregnant women with asthma tended to...
Potential roadblocks to adequate...
11/21/2023
First Report Managed Care
News
The Role of Fungi in Allergic Disease and the Evolutionary Advantage of Type 2 Immune Response
11/07/2023
Hannah Musick
This article highlights the global rise in allergic diseases and the significant economic burden they pose, focusing on the role of fungi in triggering allergic reactions and the need for further research to understand why type 2 immune...
This article highlights the global rise in allergic diseases and the significant economic burden they pose, focusing on the role of fungi in triggering allergic reactions and the need for further research to understand why type 2 immune...
This article highlights the...
11/07/2023
First Report Managed Care
News
Biologics for Asthma: Targeting Type 2 Inflammation in Severe Cases
10/13/2023
Danielle Sposato
Currently, most biologics used to treat asthma are approved for individuals with uncontrolled moderate-to-severe asthma and elevated biomarkers of type 2 (T2) inflammation, driven by T2 cytokines like IL-4, IL-13, and IL-5, according to a...
Currently, most biologics used to treat asthma are approved for individuals with uncontrolled moderate-to-severe asthma and elevated biomarkers of type 2 (T2) inflammation, driven by T2 cytokines like IL-4, IL-13, and IL-5, according to a...
Currently, most biologics used...
10/13/2023
First Report Managed Care
News
Satellite Data Reveals a Link Between NO2 Exposure and Asthma Exacerbations
10/02/2023
Lisa Kuhns, PhD, MD
Incorporating ground-level satellite-derived estimates of NO2 into multivariable models reveals a relationship between NO2 exposure and asthma exacerbations, according to a study published in AMIA Joint Summits on Translational Science.
Incorporating ground-level satellite-derived estimates of NO2 into multivariable models reveals a relationship between NO2 exposure and asthma exacerbations, according to a study published in AMIA Joint Summits on Translational Science.
Incorporating ground-level...
10/02/2023
First Report Managed Care
News
Using Socioeconomic, Insurance Status to Help Identify Risk Factors for Uncontrolled Asthma in a US Cohort
09/20/2023
Julie Gould
"Socioeconomic and insurance status, asthma severity, and prior health care utilization have been shown to predict the risk of hospitalization, in the US," explained authors. "Thus, identifying patients who are at the higher risk for...
"Socioeconomic and insurance status, asthma severity, and prior health care utilization have been shown to predict the risk of hospitalization, in the US," explained authors. "Thus, identifying patients who are at the higher risk for...
"Socioeconomic and insurance...
09/20/2023
First Report Managed Care
News
Modulating ILC2s in Allergic Airway Inflammation for Therapeutic Intervention
09/18/2023
Danielle Sposato
In a study addressing limitations in previous research, scientists investigate the role of acetylcholine (ACh) in allergic airway inflammation, emphasizing the challenges in distinguishing direct effects on group 2 innate lymphoid cells...
In a study addressing limitations in previous research, scientists investigate the role of acetylcholine (ACh) in allergic airway inflammation, emphasizing the challenges in distinguishing direct effects on group 2 innate lymphoid cells...
In a study addressing...
09/18/2023
First Report Managed Care
News
Ongoing Study of IL-23 in Asthma May Yield More Treatment Options
09/11/2023
Jolynn Tumolo
A new study suggests that gaining a better understanding of the relationship between interleukin (IL)-23 and airway inflammation in asthma patients could lead to alternative treatment options beyond traditional anti-type 2 inflammatory...
A new study suggests that gaining a better understanding of the relationship between interleukin (IL)-23 and airway inflammation in asthma patients could lead to alternative treatment options beyond traditional anti-type 2 inflammatory...
A new study suggests that...
09/11/2023
First Report Managed Care
News
New Platform Leverages Real-World Evidence for Type 2 Inflammation Immunological Disease Research
08/07/2023
Hannah Musick
Researchers introduce Immunolab, a platform that generates real-world evidence to provide insights and conduct research on immunological diseases related to type 2 inflammation.
Researchers introduce Immunolab, a platform that generates real-world evidence to provide insights and conduct research on immunological diseases related to type 2 inflammation.
Researchers introduce Immunolab,...
08/07/2023
First Report Managed Care
News
Therapy Benefits People With Type 2 Asthma Regardless of Inhaled Corticosteroid Dose
08/01/2023
Jolynn Tumolo
New findings indicate a biologic therapy was efficacious for up to 3 years in patients with uncontrolled, moderate-to-severe asthma.
New findings indicate a biologic therapy was efficacious for up to 3 years in patients with uncontrolled, moderate-to-severe asthma.
New findings indicate a biologic...
08/01/2023
First Report Managed Care

Newsfeed

News
Utilization Increases and Spending Decreases With Preventive Drug Lists for Asthma Medications
11/29/2023
Lisa Kuhns, PhD, MD
Reducing cost-sharing for asthma medications through a preventive drug list (PDL) increases adherence to controller medications, according to a study published in JAMA Network Open.
Reducing cost-sharing for asthma medications through a preventive drug list (PDL) increases adherence to controller medications, according to a study published in JAMA Network Open.
Reducing cost-sharing for asthma...
11/29/2023
First Report Managed Care
News
Asthma Management Critical During Pregnancy
11/21/2023
Jolynn Tumolo
Potential roadblocks to adequate management of asthma in pregnant women include nonadherence to medication, lack of education, and smoking habits. The review mentions a retrospective study that found pregnant women with asthma tended to...
Potential roadblocks to adequate management of asthma in pregnant women include nonadherence to medication, lack of education, and smoking habits. The review mentions a retrospective study that found pregnant women with asthma tended to...
Potential roadblocks to adequate...
11/21/2023
First Report Managed Care
News
The Role of Fungi in Allergic Disease and the Evolutionary Advantage of Type 2 Immune Response
11/07/2023
Hannah Musick
This article highlights the global rise in allergic diseases and the significant economic burden they pose, focusing on the role of fungi in triggering allergic reactions and the need for further research to understand why type 2 immune...
This article highlights the global rise in allergic diseases and the significant economic burden they pose, focusing on the role of fungi in triggering allergic reactions and the need for further research to understand why type 2 immune...
This article highlights the...
11/07/2023
First Report Managed Care
News
Biologics for Asthma: Targeting Type 2 Inflammation in Severe Cases
10/13/2023
Danielle Sposato
Currently, most biologics used to treat asthma are approved for individuals with uncontrolled moderate-to-severe asthma and elevated biomarkers of type 2 (T2) inflammation, driven by T2 cytokines like IL-4, IL-13, and IL-5, according to a...
Currently, most biologics used to treat asthma are approved for individuals with uncontrolled moderate-to-severe asthma and elevated biomarkers of type 2 (T2) inflammation, driven by T2 cytokines like IL-4, IL-13, and IL-5, according to a...
Currently, most biologics used...
10/13/2023
First Report Managed Care
News
Satellite Data Reveals a Link Between NO2 Exposure and Asthma Exacerbations
10/02/2023
Lisa Kuhns, PhD, MD
Incorporating ground-level satellite-derived estimates of NO2 into multivariable models reveals a relationship between NO2 exposure and asthma exacerbations, according to a study published in AMIA Joint Summits on Translational Science.
Incorporating ground-level satellite-derived estimates of NO2 into multivariable models reveals a relationship between NO2 exposure and asthma exacerbations, according to a study published in AMIA Joint Summits on Translational Science.
Incorporating ground-level...
10/02/2023
First Report Managed Care
News
Using Socioeconomic, Insurance Status to Help Identify Risk Factors for Uncontrolled Asthma in a US Cohort
09/20/2023
Julie Gould
"Socioeconomic and insurance status, asthma severity, and prior health care utilization have been shown to predict the risk of hospitalization, in the US," explained authors. "Thus, identifying patients who are at the higher risk for...
"Socioeconomic and insurance status, asthma severity, and prior health care utilization have been shown to predict the risk of hospitalization, in the US," explained authors. "Thus, identifying patients who are at the higher risk for...
"Socioeconomic and insurance...
09/20/2023
First Report Managed Care
News
Modulating ILC2s in Allergic Airway Inflammation for Therapeutic Intervention
09/18/2023
Danielle Sposato
In a study addressing limitations in previous research, scientists investigate the role of acetylcholine (ACh) in allergic airway inflammation, emphasizing the challenges in distinguishing direct effects on group 2 innate lymphoid cells...
In a study addressing limitations in previous research, scientists investigate the role of acetylcholine (ACh) in allergic airway inflammation, emphasizing the challenges in distinguishing direct effects on group 2 innate lymphoid cells...
In a study addressing...
09/18/2023
First Report Managed Care
News
Ongoing Study of IL-23 in Asthma May Yield More Treatment Options
09/11/2023
Jolynn Tumolo
A new study suggests that gaining a better understanding of the relationship between interleukin (IL)-23 and airway inflammation in asthma patients could lead to alternative treatment options beyond traditional anti-type 2 inflammatory...
A new study suggests that gaining a better understanding of the relationship between interleukin (IL)-23 and airway inflammation in asthma patients could lead to alternative treatment options beyond traditional anti-type 2 inflammatory...
A new study suggests that...
09/11/2023
First Report Managed Care
News
New Platform Leverages Real-World Evidence for Type 2 Inflammation Immunological Disease Research
08/07/2023
Hannah Musick
Researchers introduce Immunolab, a platform that generates real-world evidence to provide insights and conduct research on immunological diseases related to type 2 inflammation.
Researchers introduce Immunolab, a platform that generates real-world evidence to provide insights and conduct research on immunological diseases related to type 2 inflammation.
Researchers introduce Immunolab,...
08/07/2023
First Report Managed Care
News
Therapy Benefits People With Type 2 Asthma Regardless of Inhaled Corticosteroid Dose
08/01/2023
Jolynn Tumolo
New findings indicate a biologic therapy was efficacious for up to 3 years in patients with uncontrolled, moderate-to-severe asthma.
New findings indicate a biologic therapy was efficacious for up to 3 years in patients with uncontrolled, moderate-to-severe asthma.
New findings indicate a biologic...
08/01/2023
First Report Managed Care
Behind the Bill
CMS Finalizes Federal IDR Rule to Streamline No Surprises Act Dispute Resolution
05/29/2026
Grace Taylor, MS, MA
The Centers for Medicare & Medicaid Services (CMS) has finalized updates to the federal Independent Dispute Resolution (IDR) process under the No Surprises Act, lowering administrative fees, creating a centralized dispute portal, and...
The Centers for Medicare & Medicaid Services (CMS) has finalized updates to the federal Independent Dispute Resolution (IDR) process under the No Surprises Act, lowering administrative fees, creating a centralized dispute portal, and...
The Centers for Medicare &...
05/29/2026
First Report Managed Care
News
Differences in OUD Treatment Coverage Across Medicaid Managed Care Plans From 2015 to 2019
05/26/2026
Rebecca Amrick
From 2015 to 2019, Medicaid coverage of opioid use disorder (OUD) increased while plans covering treatment services decreased, raising concerns about substance use care plans and treating patients with addiction.
From 2015 to 2019, Medicaid coverage of opioid use disorder (OUD) increased while plans covering treatment services decreased, raising concerns about substance use care plans and treating patients with addiction.
From 2015 to 2019, Medicaid...
05/26/2026
First Report Managed Care
News
Linvoseltamab Demonstrates Lower Care Costs than Teclistamab and Elranatamab for TCE RRMM
05/26/2026
Rebecca Amrick
Linvoseltamab demonstrates lower and comparable care costs compared to teclistamab and elranatamab, appearing as a possible lower-cost alternative for treating patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma...
Linvoseltamab demonstrates lower and comparable care costs compared to teclistamab and elranatamab, appearing as a possible lower-cost alternative for treating patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma...
Linvoseltamab demonstrates lower...
05/26/2026
First Report Managed Care
News
Comorbidities Increase Clinical and Economic Burden for Patients With Chronic Kidney Disease
05/22/2026
Rebecca Amrick
The clinical and economic burden of chronic kidney disease (CKD) is increased when combined with comorbidities such as type 2 diabetes and heart failure, highlighting the need for improved policies and procedures to optimize disease...
The clinical and economic burden of chronic kidney disease (CKD) is increased when combined with comorbidities such as type 2 diabetes and heart failure, highlighting the need for improved policies and procedures to optimize disease...
The clinical and economic burden...
05/22/2026
First Report Managed Care
News
Pembrolizumab Plus Chemotherapy Improves Survival in mNSCLC at Higher Cost
05/22/2026
Rebecca Amrick
Pembrolizumab plus chemotherapy demonstrates more clinical efficiency in treating patients with metastatic non–small cell lung cancer (mNSCLC), but prolonged survival leads to higher overall health care costs.
Pembrolizumab plus chemotherapy demonstrates more clinical efficiency in treating patients with metastatic non–small cell lung cancer (mNSCLC), but prolonged survival leads to higher overall health care costs.
Pembrolizumab plus chemotherapy...
05/22/2026
First Report Managed Care
Behind the Bill
Congress Targets Enforcement Gaps in the No Surprises Act
05/22/2026
Hannah Musick
A bipartisan bill aims to strengthen enforcement of the No Surprises Act amid growing concerns that some health plans are failing to comply with binding payment decisions in the federal dispute resolution process.
A bipartisan bill aims to strengthen enforcement of the No Surprises Act amid growing concerns that some health plans are failing to comply with binding payment decisions in the federal dispute resolution process.
A bipartisan bill aims to...
05/22/2026
First Report Managed Care
News
Asciminib Shows Durable Frontline Benefit in Newly Diagnosed CML
05/20/2026
Hannah Musick
At 96 weeks, asciminib demonstrated higher major molecular response rates and fewer treatment discontinuations due to adverse events compared with imatinib and second-generation tyrosine kinase inhibitors in newly diagnosed chronic myeloid...
At 96 weeks, asciminib demonstrated higher major molecular response rates and fewer treatment discontinuations due to adverse events compared with imatinib and second-generation tyrosine kinase inhibitors in newly diagnosed chronic myeloid...
At 96 weeks, asciminib...
05/20/2026
First Report Managed Care
News
The Effect of Nephologist Affiliation on PD Utilization for Patients With ESKD
05/20/2026
Rebecca Amrick
A retrospective study found that physician-facility alignment influenced treatment for patients with end-stage kidney disease (ESKD) and had a higher likelihood of promoting home-based therapies such as peritoneal dialysis (PD).
A retrospective study found that physician-facility alignment influenced treatment for patients with end-stage kidney disease (ESKD) and had a higher likelihood of promoting home-based therapies such as peritoneal dialysis (PD).
A retrospective study found that...
05/20/2026
First Report Managed Care
News
Ponatinib Demonstrates Greater Clinical Benefit Than Imatinib but With Significantly Higher Care Costs
05/20/2026
Rebecca Amrick
The tyrosine kinase inhibitor (TKI) ponatinib has demonstrated moderately better patient outcomes than imatinib, but its higher costs may complicate treatment decision-making for patients, payers, and providers when it comes to managing...
The tyrosine kinase inhibitor (TKI) ponatinib has demonstrated moderately better patient outcomes than imatinib, but its higher costs may complicate treatment decision-making for patients, payers, and providers when it comes to managing...
The tyrosine kinase inhibitor...
05/20/2026
First Report Managed Care
News
Severe Alcohol-Associated Hepatitis Raises Health Care Costs Across Multiple Care Settings
05/18/2026
Rebecca Amrick
Immediate care for alcohol-associated hepatitis (AH) greatly raises health care costs across outpatient, emergency department (ED), and inpatient settings, reflecting the economic impact of AH severity and its comorbidities.
Immediate care for alcohol-associated hepatitis (AH) greatly raises health care costs across outpatient, emergency department (ED), and inpatient settings, reflecting the economic impact of AH severity and its comorbidities.
Immediate care for...
05/18/2026
First Report Managed Care
First Report Managed Care

Current Issue

March 2026
Volume 23
Issue 1
Current Issue
Issue Archive

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use